Eric Venker is Chief Executive Officer of Immunovant, Inc. (IMVT). The company reported total compensation of $20,158,767 for fiscal year 2026.
| Salary | $636,618 |
|---|---|
| Bonus | $503,345 |
| Stock awards | $0 |
| Option awards | $19,010,639 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $8,165 |
| Total | $20,158,767 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Immunovant, Inc. filed July 22, 2026, accession 0001764013-26-000092.
| Peer-group chief executive median | $9,125,787 |
|---|---|
| Difference from that median | $11,032,981 |
| Percentile within the disclosed peer group | 94th |
| Peers with a disclosed figure | 14 |
Medians and percentiles are computed across the peer group Immunovant, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2026 total |
|---|---|---|
| Eric Venker this page | Chief Executive Officer | $20,158,767 |
| Peter Salzmann | Former Chief Executive Officer | $15,334,600 |
| Tiago Girão | Chief Financial Officer | $7,616,437 |
| Michael Geffner | Former Chief Medical Officer | $5,254,089 |
| Eva Renee Barnett | Former Chief Financial Officer | $3,227,452 |
| Melanie Gloria | Chief Operating Officer | $3,067,112 |
| Jay Stout | Chief Technology Officer | $3,065,721 |
| Christopher Van Tuyl | Chief Legal Officer and Corporate Secretary | $2,295,777 |
The company's named executive officers for fiscal year 2026, and what it reported for each. See the full Immunovant, Inc. compensation brief.
Eric Venker's compensation sits inside Immunovant, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.